0.8438  -0.101 (-10.69%)		06-17 13:16
Open: 0.81 High: 0.85 Volume: 1,266,119		Pre. Close: 0.9448 Low: 0.8 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	1.92	1-year :	2.54
Resists	First :	1.64	Second :	2.17
Pivot price	1.52
Supports	First :	0.8	Second :	0.66
MAs	MA(5) :	1.25	MA(20) :	1.55
	MA(100) :	1.98	MA(250) :	3.64
MACD	MACD :	-0.3	Signal :	-0.2
%K %D	K(14,3) :	1.2	D(3) :	5.2
RSI	RSI(14): 24.3
52-week	High :	13.8	Low :	0.69

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIAF ] has closed below the lower bollinger band by 12.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.3 - 1.31	1.31 - 1.32
Low:	0.93 - 0.93	0.93 - 0.94
Close:	0.93 - 0.95	0.95 - 0.95

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Wed, 17 Jun 2026
bioAffinity sells 4M shares, aiming to raise $3.2M - Stock Titan

Wed, 17 Jun 2026
bioAffinity prices $3.2M stock sale, closing expected June 18 - Stock Titan

Wed, 17 Jun 2026
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan

Tue, 16 Jun 2026
bioAffinity (BIAF) S-1/A adds placement agency pact and warrant forms - Stock Titan

Tue, 16 Jun 2026
bioAffinity Technologies to host July 21 webinar on veteran lung screening with Philips and 4DMedical - TradingView

Tue, 16 Jun 2026
Veterans face higher lung cancer risk; new webinar explores screening tools - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	5 (M)
Shares Float	4 (M)
Held by Insiders	3.1 (%)
Held by Institutions	9 (%)
Shares Short	445 (K)
Shares Short P.Month	676 (K)

EPS	-4.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.81
Profit Margin	-280.6 %
Operating Margin	-267.7 %
Return on Assets (ttm)	-107.2 %
Return on Equity (ttm)	-622.7 %
Qtrly Rev. Growth	-27.2 %
Gross Profit (p.s.)	0.41
Sales Per Share	1.24
EBITDA (p.s.)	-2.46
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-0.18
PEG Ratio	0
Price to Book value	1.02
Price to Sales	0.66
Price to Cash Flow	-0.35

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.